Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01957956 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT01957956: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT01957956 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01957956, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vaccine therapy and temozolomide may be an effective treatment for glioblastoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Temozolomide
- BIOLOGICAL Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-11-11 |
| Est. Completion | 2016-11-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01957956
The ClinicalTrials.gov registry entry for NCT01957956 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01957956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01957956 about?
NCT01957956 is a clinical study titled "Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma". This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, s...
What is the current status of trial NCT01957956?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2013-11-11. Estimated completion is 2016-11-16.
What interventions are being tested in trial NCT01957956?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Temozolomide (DRUG), Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01957956?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.